# US 2026/0083706 A1 · 5ht agonists for treating disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083706 A1
- Document ID: US20260083706A1
- Status: Published application
- Kind: A1
- Application number: 19/222,750
- Filed: 2025-05-29
- Published: 2026-03-26
- Earliest claimed: 2015-02-25
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Scott C. Baraban
- Web page: https://patentgrep.com/patent/US20260083706A1

## CPC

- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided, inter alia, are methods for treating an epilepsy disorder using a 5HT receptor agonist, or a pharmaceutically acceptable salt thereof.

## Claims

### Claim at position 1

-58. (canceled)

### Claim 59

A method of treating Dravet syndrome, said method comprising administering to a subject in need thereof a therapeutically effective amount of a 5HT receptor agonist, wherein said 5HT receptor agonist is clemizole, a clemizole analog, or a pharmaceutically acceptable salt thereof, and wherein said subject has a cardiovascular disease, is resistant to treatment with a serotonin reuptake inhibitor, or susceptible to side effects when administered a serotonin reuptake inhibitor.

### Claim 60 (depends on 59)

The method of claim 59, wherein said 5HT receptor agonist is not a serotonin reuptake inhibitor.

### Claim 61 (depends on 59)

The method of claim 59, wherein said clemizole, a clemizole analog, or a pharmaceutically acceptable salt thereof inhibits compulsive behaviors or electrographic seizures in said subject when compared to the absence of said clemizole, a clemizole analog, or a pharmaceutically acceptable salt thereof.

### Claim 62 (depends on 59)

The method of claim 59, wherein said clemizole, a clemizole analog, or a pharmaceutically acceptable salt thereof reduces the incidence of unprovoked seizures in said subject when compared to the absence of said clemizole, a clemizole analog, or a pharmaceutically acceptable salt thereof.

### Claim 63 (depends on 59)

The method of claim 59, wherein said clemizole, a clemizole analog, or a pharmaceutically acceptable salt thereof reduces or prevents myoclonus seizures or status epilepticus in said subject when compared to the absence of said clemizole, a clemizole analog, or a pharmaceutically acceptable salt thereof.

### Claim 64 (depends on 59)

The method of claim 59, wherein said 5HT receptor agonist is administered to said subject at an amount of about 0.1 mg to about 1000 mg per kg body weight.

### Claim 65 (depends on 59)

The method of claim 59, further comprising an anti-epilepsy drug (AED).

### Claim 66 (depends on 65)

The method of claim 65, wherein said AED is acetazolamide, benzodiazepine, carbamazepine, clobazam, clonazepam, eslicarbazepine acetate, ethosuximide, ethotoin, felbamate, fenfluramine, fosphenytoin, gabapentin, ganaxolone, huperzine A, lacosamide, lamotrigine, levetiracetam, nitrazepam, oxcarbazepine, perampanel, piracetam, phenobarbital, phenytoin, potassium bromide, pregabalin, primidone, retigabine, rufinamide, valproic acid, sodium valproate, stiripentol, tiagabine, topiramate, vigabatrin, or zonisamide.

### Claim 67 (depends on 59)

The method of claim 59, wherein said clemizole, clemizole analog, or pharmaceutically acceptable salt thereof forms a pharmaceutical composition.

### Claim 68 (depends on 67)

The method of claim 67, wherein said pharmaceutical composition comprises a therapeutically effective amount of said clemizole, clemizole analog, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 69 (depends on 67)

The method of claim 67, wherein said pharmaceutical composition is co-administered with an anti-epileptic drug (AED).

### Claim 70 (depends on 67)

The method of claim 67, wherein said pharmaceutical composition comprises said clemizole, clemizole analog, or pharmaceutically acceptable salt thereof, and an AED.

### Claim 71 (depends on 59)

The method of claim 59, wherein said pharmaceutically acceptable salt is clemizole HCl.

### Claim 72

A method of treating Ohtahara syndrome, said method comprising administering to a subject in need thereof a therapeutically effective amount of a 5HT receptor agonist, wherein said 5HT receptor agonist is clemizole, a clemizole analog, or a pharmaceutically acceptable salt thereof.

### Claim 73 (depends on 72)

The method of claim 72, further comprising an anti-epilepsy drug (AED).

### Claim 74

A method of treating an early myoclonic encephalopathy, said method comprising administering to a subject in need thereof a therapeutically effective amount of a 5HT receptor agonist, wherein said 5HT receptor agonist is clemizole, a clemizole analog, or a pharmaceutically acceptable salt thereof.

### Claim 75 (depends on 74)

The method of claim 74, further comprising an anti-epilepsy drug (AED).
